Literature DB >> 9163474

Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens.

L S Garcia1, R Y Shimizu.   

Abstract

It is well known that Giardia lamblia and Cryptosporidium parvum can cause severe symptoms in humans, particularly those who are immunologically compromised. Immunoassay procedures offer both increased sensitivity and specificity compared to conventional staining methods. These reagents are also helpful when screening large numbers of patients, particularly in an outbreak situation or when screening patients with minimal symptoms. The data obtained by using 9 diagnostic kits were compared: direct fluorescent-antibody assay (DFA) kits (TechLab Giardia/Crypto IF kit, TechLab Crypto IF kit, and Meridian Merifluor Cryptosporidium/Giardia) and enzyme immunoassay (EIA) kits (Alexon ProSpecT Giardia EZ Microplate Assay, Alexon ProSpecT Cryptosporidium Microplate Assay, Cambridge Giardia lamblia Antigen Microwell ELISA, Meridian Premier Giardia lamblia, Meridian Premier Cryptosporidium, TechLab Giardia CELISA, Trend Giardia lamblia EIA). The test with the Meridian Merifluor Cryptosporidium/Giardia kit was used as the reference method. In various combinations, 60 specimens positive for Giardia, 60 specimens positive for Cryptosporidium, 40 specimens positive for a Giardia-Cryptosporidium mix, and 50 negative fecal specimens were tested. Different species (nine protozoa, three coccidia, one microsporidium, five nematodes, three cestodes, and one trematode) were included in the negative specimens. The sensitivity of EIA for Giardia ranged from 94% (Alexon) to 99% (Trend and Cambridge); the specificity was 100% with all EIA kits tested. The sensitivity of EIA for Cryptosporidium ranged from 98% (Alexon) to 99% (Meridian Premier); specificities were 100%. All DFA results were in agreement, with 100% sensitivity and specificity; however, the TechLab reagents resulted in fluorescence intensity that was generally one level below that seen with the reagents used in the reference method. In addition to sensitivity and specificity, factors such as cost, simplicity, ease of interpretation of results (color, intensity of fluorescence), equipment, available personnel, and number of tests ordered are also important considerations prior to kit selection.

Entities:  

Mesh:

Year:  1997        PMID: 9163474      PMCID: PMC229779          DOI: 10.1128/jcm.35.6.1526-1529.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  A communitywide outbreak of giardiasis with evidence of transmission by a municipal water supply.

Authors:  P K Shaw; R E Brodsky; D O Lyman; B T Wood; C P Hibler; G R Healy; K I Macleod; W Stahl; M G Schultz
Journal:  Ann Intern Med       Date:  1977-10       Impact factor: 25.391

2.  Large community outbreak of cryptosporidiosis due to contamination of a filtered public water supply.

Authors:  E B Hayes; T D Matte; T R O'Brien; T W McKinley; G S Logsdon; J B Rose; B L Ungar; D M Word; P F Pinsky; M L Cummings
Journal:  N Engl J Med       Date:  1989-05-25       Impact factor: 91.245

3.  Massive outbreak of waterborne cryptosporidium infection in Milwaukee, Wisconsin: recurrence of illness and risk of secondary transmission.

Authors:  W R MacKenzie; W L Schell; K A Blair; D G Addiss; D E Peterson; N J Hoxie; J J Kazmierczak; J P Davis
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

4.  Usefulness of an enzyme-linked immunosorbent assay for detection of Giardia antigen in feces.

Authors:  T E Nash; D A Herrington; M M Levine
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

5.  Enzyme-linked immunosorbent assay for the detection of Giardia lamblia in fecal specimens.

Authors:  B L Ungar; R H Yolken; T E Nash; T C Quinn
Journal:  J Infect Dis       Date:  1984-01       Impact factor: 5.226

6.  Evaluation of a commercially available enzyme-linked immunosorbent assay for Giardia lamblia antigen in stool.

Authors:  D G Addiss; H M Mathews; J M Stewart; S P Wahlquist; R M Williams; R J Finton; H C Spencer; D D Juranek
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

7.  Spiramycin in the treatment of cryptosporidiosis.

Authors:  A M Pilla; M J Rybak; P H Chandrasekar
Journal:  Pharmacotherapy       Date:  1987       Impact factor: 4.705

8.  Detection of Giardia lamblia by immunofluorescence.

Authors:  J L Riggs; K W Dupuis; K Nakamura; D P Spath
Journal:  Appl Environ Microbiol       Date:  1983-02       Impact factor: 4.792

9.  Cryptosporidium infection in Oregon public health clinic patients 1985-88: the value of statewide laboratory surveillance.

Authors:  M R Skeels; R Sokolow; C V Hubbard; J K Andrus; J Baisch
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

10.  Diagnosis of giardiasis by two methods. Immunofluorescence and enzyme-linked immunosorbent assay.

Authors:  M Wittner; S Maayan; W Farrer; H B Tanowitz
Journal:  Arch Pathol Lab Med       Date:  1983-10       Impact factor: 5.534

View more
  80 in total

1.  Evaluation of a combination rapid immunoassay for detection of Giardia and Cryptosporidium antigens.

Authors:  R Chan; J Chen; M K York; N Setijono; R L Kaplan; F Graham; H B Tanowitz
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Evaluation of ColorPAC Giardia/Cryptosporidium rapid assay and ProSpecT Giardia/Cryptosporidium microplate assay for detection of Giardia and Cryptosporidium in fecal specimens.

Authors:  M T Katanik; S K Schneider; J E Rosenblatt; G S Hall; G W Procop
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Cryptosporidiosis: comparison of three diagnostic methods and effects of storage temperature on detectability of cryptosporidia in cattle faeces.

Authors:  Yvonne Kuhnert-Paul; Berit Bangoura; Katja Dittmar; Arwid Daugschies; Ronald Schmäschke
Journal:  Parasitol Res       Date:  2012-01-14       Impact factor: 2.289

4.  Rapid and accurate detection of Giardia lamblia and Cryptosporidium spp. antigens in human fecal specimens by new commercially available qualitative immunochromatographic assays.

Authors:  T Regnath; T Klemm; R Ignatius
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

5.  Comparison of diagnostic techniques for the detection of Cryptosporidium oocysts in animal samples.

Authors:  Marzieh Ezzaty Mirhashemi; Annetta Zintl; Tim Grant; Frances E Lucy; Grace Mulcahy; Theo De Waal
Journal:  Exp Parasitol       Date:  2015-02-03       Impact factor: 2.011

6.  Evaluation of four commercial rapid immunochromatographic assays for detection of Cryptosporidium antigens in stool samples: a blind multicenter trial.

Authors:  Patrice Agnamey; Claudine Sarfati; Claudine Pinel; Meja Rabodoniriina; Nathalie Kapel; Emmanuel Dutoit; Cécile Garnaud; Momar Diouf; Jean-François Garin; Anne Totet; F Derouin
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

7.  Detection and genotyping of Giardia intestinalis isolates using intergenic spacers(IGS)-based PCR.

Authors:  Jong-Ho Lee; Jongweon Lee; Soon-Jung Park; Tai-Soon Yong; Ui-Wook Hwang
Journal:  Korean J Parasitol       Date:  2006-12       Impact factor: 1.341

8.  Epidemiology of Cyclospora cayetanensis and other intestinal parasites in a community in Haiti.

Authors:  Adriana S Lopez; Jean M Bendik; Jean Y Alliance; Jacquelin M Roberts; Alexandre J da Silva; Iaci N S Moura; Michael J Arrowood; Mark L Eberhard; Barbara L Herwaldt
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Parasitic colitides.

Authors:  Joel E Goldberg
Journal:  Clin Colon Rectal Surg       Date:  2007-02

10.  Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens.

Authors:  Stephanie P Johnston; Melissa M Ballard; Michael J Beach; Louise Causer; Patricia P Wilkins
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.